title: 5q- in a case of chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
abstract: Clonal chromosome and/or hematological abnormalities typically observed in myelodysplastic syndromes (MDS) have been described with increased frequency after autologous bone marrow transplantation (BMT) for lymphoma. We report the case of a woman with chronic myelogenous leukemia (CML) allografted with her HLA-identical sibling who, 5 years after the transplant and under immunosuppressive treatment for chronic graft host disease (GVHD), suffered a cytogenetic relapse associated with a 5q- deletion in the host metaphases. These findings suggest that myelodysplastic changes, possibly related to the chemo-radiotherapy conditioning regimen, may also present after allogeneic BMT.
authors.affiliation: Centro Trapianti di Midollo, Ospedale Maggiore IRCCS, Milano, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Soligo
authors.forename: L
authors.initials: L
authors.lastname: Romitti
authors.forename: V
authors.initials: V
authors.lastname: Bertolli
authors.forename: A
authors.initials: A
authors.lastname: Della Volpe
authors.forename: C
authors.initials: C
authors.lastname: Annaloro
authors.forename: G
authors.initials: G
authors.lastname: Lambertenghi Deliliers
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002872:Chromosome Deletion; D002877:Chromosomes, Human / Q000187:drug effects / Q000528:radiation effects; D002895:Chromosomes, Human, Pair 5 / Q000648:ultrastructure*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects*; D016572:Cyclosporine / Q000627:therapeutic use; D004802:Eosinophilia / Q000188:drug therapy; D005208:Fasciitis / Q000188:drug therapy; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use; D012008:Recurrence; D014916:Whole-Body Irradiation / Q000009:adverse effects*
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide; D001379:Azathioprine; D006918:Hydroxyurea; D008727:Methotrexate